Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.
Identifieur interne : 000266 ( PubMed/Corpus ); précédent : 000265; suivant : 000267Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.
Auteurs : Maria Vittoria Dieci ; Nina Radosevic-Robin ; Susan Fineberg ; Gert Van Den Eynden ; Nils Ternes ; Frederique Penault-Llorca ; Giancarlo Pruneri ; Timothy M. D'Alfonso ; Sandra Demaria ; Carlos Castaneda ; Joselyn Sanchez ; Sunil Badve ; Stefan Michiels ; Veerle Bossuyt ; Federico Rojo ; Baljit Singh ; Torsten Nielsen ; Giuseppe Viale ; Seong-Rim Kim ; Stephen Hewitt ; Stephan Wienert ; Sybille Loibl ; David Rimm ; Fraser Symmans ; Carsten Denkert ; Sylvia Adams ; Sherene Loi ; Roberto SalgadoSource :
- Seminars in cancer biology [ 1096-3650 ] ; 2017.
Abstract
Morphological evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer is gaining momentum as evidence strengthens the clinical relevance of this immunological biomarker. TILs in the post-neoadjuvant residual disease setting are acquiring increasing importance as a stratifying marker in clinical trials, considering the raising interest on immunotherapeutic strategies after neoadjuvant chemotherapy. TILs in ductal carcinoma in situ, with or without invasive carcinoma, represent an emerging area of clinical breast cancer research. The aim of this report is to update pathologists, clinicians and researchers on TIL assessment in both the post-neoadjuvant residual disease and the ductal carcinoma in situ settings. The International Immuno-Oncology Working Group proposes a method for assessing TILs in these settings, based on the previously published International Guidelines on TIL Assessment in Breast Cancer. In this regard, these recommendations represent a consensus guidance for pathologists, aimed to achieve the highest possible consistency among future studies.
DOI: 10.1016/j.semcancer.2017.10.003
PubMed: 29024776
Links to Exploration step
pubmed:29024776Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.</title><author><name sortKey="Dieci, Maria Vittoria" sort="Dieci, Maria Vittoria" uniqKey="Dieci M" first="Maria Vittoria" last="Dieci">Maria Vittoria Dieci</name><affiliation><nlm:affiliation>Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy; Medical Oncology 2, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy. Electronic address: mariavittoriadieci@gmail.com.</nlm:affiliation></affiliation></author><author><name sortKey="Radosevic Robin, Nina" sort="Radosevic Robin, Nina" uniqKey="Radosevic Robin N" first="Nina" last="Radosevic-Robin">Nina Radosevic-Robin</name><affiliation><nlm:affiliation>Department of Surgical Pathology and Biopathology, Jean Perrin Comprehensive Cancer Centre, Clermont-Ferrand, France; Inserm/University of Auvergne U1240, Clermont-Ferrand, France.</nlm:affiliation></affiliation></author><author><name sortKey="Fineberg, Susan" sort="Fineberg, Susan" uniqKey="Fineberg S" first="Susan" last="Fineberg">Susan Fineberg</name><affiliation><nlm:affiliation>Montefiore Medical Center, Bronx, NY, USA; The Albert Einstein College of Medicine, Bronx, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Van Den Eynden, Gert" sort="Van Den Eynden, Gert" uniqKey="Van Den Eynden G" first="Gert" last="Van Den Eynden">Gert Van Den Eynden</name><affiliation><nlm:affiliation>Molecular Immunology Unit, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Department of Pathology, GZA Ziekenhuizen, Antwerp, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Ternes, Nils" sort="Ternes, Nils" uniqKey="Ternes N" first="Nils" last="Ternes">Nils Ternes</name><affiliation><nlm:affiliation>Service de Biostatistique et d'Epidémiologie, Gustave Roussy, B2 M, RdC,114 rue Edouard-Vaillant, 94805, Villejuif, France; CESP, Fac. de médecine - Univ. Paris-Sud, Fac. de médecine - UVSQ, INSERM, Université Paris-Saclay, Villejuif, 94805, France.</nlm:affiliation></affiliation></author><author><name sortKey="Penault Llorca, Frederique" sort="Penault Llorca, Frederique" uniqKey="Penault Llorca F" first="Frederique" last="Penault-Llorca">Frederique Penault-Llorca</name><affiliation><nlm:affiliation>Department of Surgical Pathology and Biopathology, Jean Perrin Comprehensive Cancer Centre, Clermont-Ferrand, France; Inserm/University of Auvergne U1240, Clermont-Ferrand, France; School of Medicine, University of Auvergne, Clermont-Ferrand, France.</nlm:affiliation></affiliation></author><author><name sortKey="Pruneri, Giancarlo" sort="Pruneri, Giancarlo" uniqKey="Pruneri G" first="Giancarlo" last="Pruneri">Giancarlo Pruneri</name><affiliation><nlm:affiliation>Division of Pathology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; University of Milan, School of Medicine, Milan, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="D Alfonso, Timothy M" sort="D Alfonso, Timothy M" uniqKey="D Alfonso T" first="Timothy M" last="D'Alfonso">Timothy M. D'Alfonso</name><affiliation><nlm:affiliation>Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Demaria, Sandra" sort="Demaria, Sandra" uniqKey="Demaria S" first="Sandra" last="Demaria">Sandra Demaria</name><affiliation><nlm:affiliation>Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Castaneda, Carlos" sort="Castaneda, Carlos" uniqKey="Castaneda C" first="Carlos" last="Castaneda">Carlos Castaneda</name><affiliation><nlm:affiliation>Department of Research, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.</nlm:affiliation></affiliation></author><author><name sortKey="Sanchez, Joselyn" sort="Sanchez, Joselyn" uniqKey="Sanchez J" first="Joselyn" last="Sanchez">Joselyn Sanchez</name><affiliation><nlm:affiliation>Department of Research, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.</nlm:affiliation></affiliation></author><author><name sortKey="Badve, Sunil" sort="Badve, Sunil" uniqKey="Badve S" first="Sunil" last="Badve">Sunil Badve</name><affiliation><nlm:affiliation>Department of Pathology and Laboratory, Medicine, Indiana University, Indianapolis, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Michiels, Stefan" sort="Michiels, Stefan" uniqKey="Michiels S" first="Stefan" last="Michiels">Stefan Michiels</name><affiliation><nlm:affiliation>Service de Biostatistique et d'Epidémiologie, Gustave Roussy, B2 M, RdC,114 rue Edouard-Vaillant, 94805, Villejuif, France; CESP, Fac. de médecine - Univ. Paris-Sud, Fac. de médecine - UVSQ, INSERM, Université Paris-Saclay, Villejuif, 94805, France.</nlm:affiliation></affiliation></author><author><name sortKey="Bossuyt, Veerle" sort="Bossuyt, Veerle" uniqKey="Bossuyt V" first="Veerle" last="Bossuyt">Veerle Bossuyt</name><affiliation><nlm:affiliation>Department of Pathology, Yale University School of Medicine, New Haven, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Rojo, Federico" sort="Rojo, Federico" uniqKey="Rojo F" first="Federico" last="Rojo">Federico Rojo</name><affiliation><nlm:affiliation>Pathology Department, IIS, Fundacion Jimenez Diaz, UAM, Madrid, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Singh, Baljit" sort="Singh, Baljit" uniqKey="Singh B" first="Baljit" last="Singh">Baljit Singh</name><affiliation><nlm:affiliation>Department of Pathology, Coney Island Hospital, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Nielsen, Torsten" sort="Nielsen, Torsten" uniqKey="Nielsen T" first="Torsten" last="Nielsen">Torsten Nielsen</name><affiliation><nlm:affiliation>Genetic Pathology Evaluation Centre, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Viale, Giuseppe" sort="Viale, Giuseppe" uniqKey="Viale G" first="Giuseppe" last="Viale">Giuseppe Viale</name><affiliation><nlm:affiliation>Department of Pathology, Istituto Europeo di Oncologia, University of Milan, Milan, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Kim, Seong Rim" sort="Kim, Seong Rim" uniqKey="Kim S" first="Seong-Rim" last="Kim">Seong-Rim Kim</name><affiliation><nlm:affiliation>National Surgical Adjuvant Breast and Bowel Project Operations Center/NRG Oncology, Pittsburgh, PA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Hewitt, Stephen" sort="Hewitt, Stephen" uniqKey="Hewitt S" first="Stephen" last="Hewitt">Stephen Hewitt</name><affiliation><nlm:affiliation>Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Wienert, Stephan" sort="Wienert, Stephan" uniqKey="Wienert S" first="Stephan" last="Wienert">Stephan Wienert</name><affiliation><nlm:affiliation>dlw Laborsoftware UG (haftungsbeschränkt) Lübben, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Loibl, Sybille" sort="Loibl, Sybille" uniqKey="Loibl S" first="Sybille" last="Loibl">Sybille Loibl</name><affiliation><nlm:affiliation>German Breast Group, Neu-Isenburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Rimm, David" sort="Rimm, David" uniqKey="Rimm D" first="David" last="Rimm">David Rimm</name><affiliation><nlm:affiliation>Department of Pathology, Yale University School of Medicine, New Haven, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Symmans, Fraser" sort="Symmans, Fraser" uniqKey="Symmans F" first="Fraser" last="Symmans">Fraser Symmans</name><affiliation><nlm:affiliation>Department of Pathology, University of Texas M.D. Anderson Cancer Center, Houston, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Denkert, Carsten" sort="Denkert, Carsten" uniqKey="Denkert C" first="Carsten" last="Denkert">Carsten Denkert</name><affiliation><nlm:affiliation>Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Adams, Sylvia" sort="Adams, Sylvia" uniqKey="Adams S" first="Sylvia" last="Adams">Sylvia Adams</name><affiliation><nlm:affiliation>New York University Medical School, Perlmutter Cancer Center, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Loi, Sherene" sort="Loi, Sherene" uniqKey="Loi S" first="Sherene" last="Loi">Sherene Loi</name><affiliation><nlm:affiliation>Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Salgado, Roberto" sort="Salgado, Roberto" uniqKey="Salgado R" first="Roberto" last="Salgado">Roberto Salgado</name><affiliation><nlm:affiliation>Translational Breast Cancer Genomic and Therapeutics Laboratory, Peter Mac Callum Cancer Center, Victoria, Australia; Breast Cancer Translational Research Laboratory, Jules Bordet Institute, Brussels, Belgium; Department of Pathology, GZA, Antwerp, Belgium.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:29024776</idno><idno type="pmid">29024776</idno><idno type="doi">10.1016/j.semcancer.2017.10.003</idno><idno type="wicri:Area/PubMed/Corpus">000266</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000266</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.</title><author><name sortKey="Dieci, Maria Vittoria" sort="Dieci, Maria Vittoria" uniqKey="Dieci M" first="Maria Vittoria" last="Dieci">Maria Vittoria Dieci</name><affiliation><nlm:affiliation>Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy; Medical Oncology 2, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy. Electronic address: mariavittoriadieci@gmail.com.</nlm:affiliation></affiliation></author><author><name sortKey="Radosevic Robin, Nina" sort="Radosevic Robin, Nina" uniqKey="Radosevic Robin N" first="Nina" last="Radosevic-Robin">Nina Radosevic-Robin</name><affiliation><nlm:affiliation>Department of Surgical Pathology and Biopathology, Jean Perrin Comprehensive Cancer Centre, Clermont-Ferrand, France; Inserm/University of Auvergne U1240, Clermont-Ferrand, France.</nlm:affiliation></affiliation></author><author><name sortKey="Fineberg, Susan" sort="Fineberg, Susan" uniqKey="Fineberg S" first="Susan" last="Fineberg">Susan Fineberg</name><affiliation><nlm:affiliation>Montefiore Medical Center, Bronx, NY, USA; The Albert Einstein College of Medicine, Bronx, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Van Den Eynden, Gert" sort="Van Den Eynden, Gert" uniqKey="Van Den Eynden G" first="Gert" last="Van Den Eynden">Gert Van Den Eynden</name><affiliation><nlm:affiliation>Molecular Immunology Unit, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Department of Pathology, GZA Ziekenhuizen, Antwerp, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Ternes, Nils" sort="Ternes, Nils" uniqKey="Ternes N" first="Nils" last="Ternes">Nils Ternes</name><affiliation><nlm:affiliation>Service de Biostatistique et d'Epidémiologie, Gustave Roussy, B2 M, RdC,114 rue Edouard-Vaillant, 94805, Villejuif, France; CESP, Fac. de médecine - Univ. Paris-Sud, Fac. de médecine - UVSQ, INSERM, Université Paris-Saclay, Villejuif, 94805, France.</nlm:affiliation></affiliation></author><author><name sortKey="Penault Llorca, Frederique" sort="Penault Llorca, Frederique" uniqKey="Penault Llorca F" first="Frederique" last="Penault-Llorca">Frederique Penault-Llorca</name><affiliation><nlm:affiliation>Department of Surgical Pathology and Biopathology, Jean Perrin Comprehensive Cancer Centre, Clermont-Ferrand, France; Inserm/University of Auvergne U1240, Clermont-Ferrand, France; School of Medicine, University of Auvergne, Clermont-Ferrand, France.</nlm:affiliation></affiliation></author><author><name sortKey="Pruneri, Giancarlo" sort="Pruneri, Giancarlo" uniqKey="Pruneri G" first="Giancarlo" last="Pruneri">Giancarlo Pruneri</name><affiliation><nlm:affiliation>Division of Pathology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; University of Milan, School of Medicine, Milan, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="D Alfonso, Timothy M" sort="D Alfonso, Timothy M" uniqKey="D Alfonso T" first="Timothy M" last="D'Alfonso">Timothy M. D'Alfonso</name><affiliation><nlm:affiliation>Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Demaria, Sandra" sort="Demaria, Sandra" uniqKey="Demaria S" first="Sandra" last="Demaria">Sandra Demaria</name><affiliation><nlm:affiliation>Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Castaneda, Carlos" sort="Castaneda, Carlos" uniqKey="Castaneda C" first="Carlos" last="Castaneda">Carlos Castaneda</name><affiliation><nlm:affiliation>Department of Research, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.</nlm:affiliation></affiliation></author><author><name sortKey="Sanchez, Joselyn" sort="Sanchez, Joselyn" uniqKey="Sanchez J" first="Joselyn" last="Sanchez">Joselyn Sanchez</name><affiliation><nlm:affiliation>Department of Research, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.</nlm:affiliation></affiliation></author><author><name sortKey="Badve, Sunil" sort="Badve, Sunil" uniqKey="Badve S" first="Sunil" last="Badve">Sunil Badve</name><affiliation><nlm:affiliation>Department of Pathology and Laboratory, Medicine, Indiana University, Indianapolis, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Michiels, Stefan" sort="Michiels, Stefan" uniqKey="Michiels S" first="Stefan" last="Michiels">Stefan Michiels</name><affiliation><nlm:affiliation>Service de Biostatistique et d'Epidémiologie, Gustave Roussy, B2 M, RdC,114 rue Edouard-Vaillant, 94805, Villejuif, France; CESP, Fac. de médecine - Univ. Paris-Sud, Fac. de médecine - UVSQ, INSERM, Université Paris-Saclay, Villejuif, 94805, France.</nlm:affiliation></affiliation></author><author><name sortKey="Bossuyt, Veerle" sort="Bossuyt, Veerle" uniqKey="Bossuyt V" first="Veerle" last="Bossuyt">Veerle Bossuyt</name><affiliation><nlm:affiliation>Department of Pathology, Yale University School of Medicine, New Haven, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Rojo, Federico" sort="Rojo, Federico" uniqKey="Rojo F" first="Federico" last="Rojo">Federico Rojo</name><affiliation><nlm:affiliation>Pathology Department, IIS, Fundacion Jimenez Diaz, UAM, Madrid, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Singh, Baljit" sort="Singh, Baljit" uniqKey="Singh B" first="Baljit" last="Singh">Baljit Singh</name><affiliation><nlm:affiliation>Department of Pathology, Coney Island Hospital, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Nielsen, Torsten" sort="Nielsen, Torsten" uniqKey="Nielsen T" first="Torsten" last="Nielsen">Torsten Nielsen</name><affiliation><nlm:affiliation>Genetic Pathology Evaluation Centre, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Viale, Giuseppe" sort="Viale, Giuseppe" uniqKey="Viale G" first="Giuseppe" last="Viale">Giuseppe Viale</name><affiliation><nlm:affiliation>Department of Pathology, Istituto Europeo di Oncologia, University of Milan, Milan, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Kim, Seong Rim" sort="Kim, Seong Rim" uniqKey="Kim S" first="Seong-Rim" last="Kim">Seong-Rim Kim</name><affiliation><nlm:affiliation>National Surgical Adjuvant Breast and Bowel Project Operations Center/NRG Oncology, Pittsburgh, PA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Hewitt, Stephen" sort="Hewitt, Stephen" uniqKey="Hewitt S" first="Stephen" last="Hewitt">Stephen Hewitt</name><affiliation><nlm:affiliation>Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Wienert, Stephan" sort="Wienert, Stephan" uniqKey="Wienert S" first="Stephan" last="Wienert">Stephan Wienert</name><affiliation><nlm:affiliation>dlw Laborsoftware UG (haftungsbeschränkt) Lübben, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Loibl, Sybille" sort="Loibl, Sybille" uniqKey="Loibl S" first="Sybille" last="Loibl">Sybille Loibl</name><affiliation><nlm:affiliation>German Breast Group, Neu-Isenburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Rimm, David" sort="Rimm, David" uniqKey="Rimm D" first="David" last="Rimm">David Rimm</name><affiliation><nlm:affiliation>Department of Pathology, Yale University School of Medicine, New Haven, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Symmans, Fraser" sort="Symmans, Fraser" uniqKey="Symmans F" first="Fraser" last="Symmans">Fraser Symmans</name><affiliation><nlm:affiliation>Department of Pathology, University of Texas M.D. Anderson Cancer Center, Houston, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Denkert, Carsten" sort="Denkert, Carsten" uniqKey="Denkert C" first="Carsten" last="Denkert">Carsten Denkert</name><affiliation><nlm:affiliation>Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Adams, Sylvia" sort="Adams, Sylvia" uniqKey="Adams S" first="Sylvia" last="Adams">Sylvia Adams</name><affiliation><nlm:affiliation>New York University Medical School, Perlmutter Cancer Center, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Loi, Sherene" sort="Loi, Sherene" uniqKey="Loi S" first="Sherene" last="Loi">Sherene Loi</name><affiliation><nlm:affiliation>Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Salgado, Roberto" sort="Salgado, Roberto" uniqKey="Salgado R" first="Roberto" last="Salgado">Roberto Salgado</name><affiliation><nlm:affiliation>Translational Breast Cancer Genomic and Therapeutics Laboratory, Peter Mac Callum Cancer Center, Victoria, Australia; Breast Cancer Translational Research Laboratory, Jules Bordet Institute, Brussels, Belgium; Department of Pathology, GZA, Antwerp, Belgium.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Seminars in cancer biology</title><idno type="eISSN">1096-3650</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Morphological evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer is gaining momentum as evidence strengthens the clinical relevance of this immunological biomarker. TILs in the post-neoadjuvant residual disease setting are acquiring increasing importance as a stratifying marker in clinical trials, considering the raising interest on immunotherapeutic strategies after neoadjuvant chemotherapy. TILs in ductal carcinoma in situ, with or without invasive carcinoma, represent an emerging area of clinical breast cancer research. The aim of this report is to update pathologists, clinicians and researchers on TIL assessment in both the post-neoadjuvant residual disease and the ductal carcinoma in situ settings. The International Immuno-Oncology Working Group proposes a method for assessing TILs in these settings, based on the previously published International Guidelines on TIL Assessment in Breast Cancer. In this regard, these recommendations represent a consensus guidance for pathologists, aimed to achieve the highest possible consistency among future studies.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">29024776</PMID><DateCreated><Year>2017</Year><Month>10</Month><Day>12</Day></DateCreated><DateRevised><Year>2017</Year><Month>11</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-3650</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2017</Year><Month>Oct</Month><Day>09</Day></PubDate></JournalIssue><Title>Seminars in cancer biology</Title><ISOAbbreviation>Semin. Cancer Biol.</ISOAbbreviation></Journal><ArticleTitle>Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S1044-579X(17)30217-1</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.semcancer.2017.10.003</ELocationID><Abstract><AbstractText>Morphological evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer is gaining momentum as evidence strengthens the clinical relevance of this immunological biomarker. TILs in the post-neoadjuvant residual disease setting are acquiring increasing importance as a stratifying marker in clinical trials, considering the raising interest on immunotherapeutic strategies after neoadjuvant chemotherapy. TILs in ductal carcinoma in situ, with or without invasive carcinoma, represent an emerging area of clinical breast cancer research. The aim of this report is to update pathologists, clinicians and researchers on TIL assessment in both the post-neoadjuvant residual disease and the ductal carcinoma in situ settings. The International Immuno-Oncology Working Group proposes a method for assessing TILs in these settings, based on the previously published International Guidelines on TIL Assessment in Breast Cancer. In this regard, these recommendations represent a consensus guidance for pathologists, aimed to achieve the highest possible consistency among future studies.</AbstractText><CopyrightInformation>Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dieci</LastName><ForeName>Maria Vittoria</ForeName><Initials>MV</Initials><AffiliationInfo><Affiliation>Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy; Medical Oncology 2, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy. Electronic address: mariavittoriadieci@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Radosevic-Robin</LastName><ForeName>Nina</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Surgical Pathology and Biopathology, Jean Perrin Comprehensive Cancer Centre, Clermont-Ferrand, France; Inserm/University of Auvergne U1240, Clermont-Ferrand, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fineberg</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Montefiore Medical Center, Bronx, NY, USA; The Albert Einstein College of Medicine, Bronx, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Eynden</LastName><ForeName>Gert</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Molecular Immunology Unit, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Department of Pathology, GZA Ziekenhuizen, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ternes</LastName><ForeName>Nils</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Service de Biostatistique et d'Epidémiologie, Gustave Roussy, B2 M, RdC,114 rue Edouard-Vaillant, 94805, Villejuif, France; CESP, Fac. de médecine - Univ. Paris-Sud, Fac. de médecine - UVSQ, INSERM, Université Paris-Saclay, Villejuif, 94805, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Penault-Llorca</LastName><ForeName>Frederique</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Surgical Pathology and Biopathology, Jean Perrin Comprehensive Cancer Centre, Clermont-Ferrand, France; Inserm/University of Auvergne U1240, Clermont-Ferrand, France; School of Medicine, University of Auvergne, Clermont-Ferrand, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pruneri</LastName><ForeName>Giancarlo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Pathology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; University of Milan, School of Medicine, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Alfonso</LastName><ForeName>Timothy M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demaria</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castaneda</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Research, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez</LastName><ForeName>Joselyn</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Research, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Badve</LastName><ForeName>Sunil</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory, Medicine, Indiana University, Indianapolis, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michiels</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Service de Biostatistique et d'Epidémiologie, Gustave Roussy, B2 M, RdC,114 rue Edouard-Vaillant, 94805, Villejuif, France; CESP, Fac. de médecine - Univ. Paris-Sud, Fac. de médecine - UVSQ, INSERM, Université Paris-Saclay, Villejuif, 94805, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bossuyt</LastName><ForeName>Veerle</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Pathology, Yale University School of Medicine, New Haven, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rojo</LastName><ForeName>Federico</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Pathology Department, IIS, Fundacion Jimenez Diaz, UAM, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Baljit</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pathology, Coney Island Hospital, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nielsen</LastName><ForeName>Torsten</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Genetic Pathology Evaluation Centre, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Viale</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Pathology, Istituto Europeo di Oncologia, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Seong-Rim</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>National Surgical Adjuvant Breast and Bowel Project Operations Center/NRG Oncology, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hewitt</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wienert</LastName><ForeName>Stephan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>dlw Laborsoftware UG (haftungsbeschränkt) Lübben, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loibl</LastName><ForeName>Sybille</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>German Breast Group, Neu-Isenburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rimm</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Pathology, Yale University School of Medicine, New Haven, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Symmans</LastName><ForeName>Fraser</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Texas M.D. Anderson Cancer Center, Houston, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Denkert</LastName><ForeName>Carsten</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adams</LastName><ForeName>Sylvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>New York University Medical School, Perlmutter Cancer Center, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loi</LastName><ForeName>Sherene</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salgado</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Translational Breast Cancer Genomic and Therapeutics Laboratory, Peter Mac Callum Cancer Center, Victoria, Australia; Breast Cancer Translational Research Laboratory, Jules Bordet Institute, Brussels, Belgium; Department of Pathology, GZA, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>International Immuno-Oncology Biomarker Working Group on Breast Cancer</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>10</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Semin Cancer Biol</MedlineTA><NlmUniqueID>9010218</NlmUniqueID><ISSNLinking>1044-579X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Breast cancer</Keyword><Keyword MajorTopicYN="N">Ductal carcinoma in situ</Keyword><Keyword MajorTopicYN="N">Neoadjuvant</Keyword><Keyword MajorTopicYN="N">Residual cancer burden</Keyword><Keyword MajorTopicYN="N">Residual disease</Keyword><Keyword MajorTopicYN="N">Tumor-infiltrating lymphocytes</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>09</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>10</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29024776</ArticleId><ArticleId IdType="pii">S1044-579X(17)30217-1</ArticleId><ArticleId IdType="doi">10.1016/j.semcancer.2017.10.003</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000266 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000266 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:29024776
|texte= Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:29024776" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |